University of Chicago Medical Center
PUBLIC RELEASE DATE: 7-Apr-2014
The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of
amphetamine, is related to schizophrenia and ADHD.
Genetic variants associated with enjoying the effects of d-amphetamine—the active ingredient in Adderall—are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. “Some of the variants that make you like amphetamine also appear to make you less likely to develop schizophrenia and ADHD,” said study leader Abraham Palmer, PhD, associate professor of human genetics at the University of Chicago. “Our study provides new insights into the biology of
amphetamine and how it relates to the biology of risk for these psychiatric diseases.”
According to Dr. Harold Levinson, this important study indicates that people who like the effects of amphetamine would be slightly less likely to develop schizophrenia and ADHD, whereas those who did not like amphetamine are slightly more likely to develop these diseases. Levinson asks: “ Might these results suggest that those who like amphetamine are more likely to abuse this drug? If so, then we should investigate if abusers are less likely to have ADHD?”
About Harold Levinson, M.D.
Formerly Clinical Associate Professor of Psychiatry at New York University Medical Center, Dr. Harold Levinson is currently Director of the Levinson Medical Center for Learning Disabilities in Long Island, New York. He is a well-known neuropsychiatrist, clinical researcher and author. For more information, call 1(800)334-7323 or visit http://www.dyslexiaonline.com.